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Abstract
Background: Total hip (THR) and total knee replacements (TKR) are two highly successful orthopaedic procedures
that reduce pain for people with osteoarthritis. Previous evidence suggests that physical activity, at best, remains
the same pre- to post-operatively, and in some instances declines. The PEP-TALK trial evaluates the effects of a
group-based, behaviour change intervention on physical activity following a THR or TKR.
Methods: PEP-TALK is an open, phase III, pragmatic, multi-centre, parallel, two-arm, two-way superiority randomised
controlled trial investigating the effectiveness of usual care plus a behaviour change therapy compared with usual
care alone following primary THR or TKR. The primary outcome is the UCLA Activity Score at 12 months post-
randomisation which will be analysed using a linear mixed effects model. Secondary outcomes measured at 6
months and 12 months after randomisation include the UCLA Activity Score, Lower Extremity Functional Scale,
Oxford Hip/Knee Score, Numerical Rating Scale for Pain, Generalised Self-Efficacy Scale, Tampa Scale for
Kinesiophobia, Hospital Anxiety and Depression Scale, EuroQoL EQ-5D-5L index and EQ-VAS and complications or
adverse events. Full details of the planned analysis approaches for the primary and secondary outcomes, as well as
the planned sensitivity analyses to be undertaken due to the COVID-19 pandemic, are described here. The PEP-
TALK study protocol has been published previously.
Discussion: This paper provides details of the planned statistical analyses for the PEP-TALK trial. This is aimed to
reduce the risk of outcome reporting bias and enhance transparency in reporting.
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Background
This analysis strategy adheres to the Statistical Analysis
Plan Guidelines [1].
Total hip (THR) and total knee replacements (TKR)
are two highly successful orthopaedic procedures which
reduce pain for people with osteoarthritis [2, 3]. Over
230,000 THR and TKRs were performed in the UK in
2019 [2]. Approximately 90% of patients are satisfied fol-
lowing THR and TKR [3] with significant improvements
in pain and physical function after 3 to 12months [3, 4].
However, medical co-morbidities are common in this
population. These include hypertension (56%) [5], car-
diovascular disease (20%) [6], diabetes (16%) [6] and
multi-joint pain (57%) [5]. Twenty-seven per cent of
people who undergo joint replacement have three to
four comorbidities [6]. Medical comorbidities such as
these have a significant negative impact on both health-
related quality of life and societal burden [7, 8].
Historically, it has been assumed that people are more
active following THR or TKR through the amelioration
of their joint pain [9]. However, previous evidence has
indicated that physical activity, at best, remains the same
from pre- to post-operatively, and in some instances de-
clines [9]. There does not appear to be a difference in
physical activity trajectories between those following
THR or TKR [9, 10]. The reasons for reduced participa-
tion may differ between the groups [10] with TKR more
often associated with increased pain in the initial 12
post-operative months compared to THR [3, 4], whereas
those with THR may have greater fear avoidance
through the risks of joint implant dislocation [3, 4].
Subsequent analyses from large USA and UK datasets
have supported this finding, re-enforcing the notion that
physical activity is lower after THR and TKR compared
to age- and gender-matched cohorts who had not under-
gone joint replacement [10]. Given that physical activity
can significantly reduce symptoms associated with com-
mon comorbidities [11], this population’s physical in-
activity has a detrimental effect on their health.
Participating in regular physical activity can decrease the
risk of cardiovascular disease by 52% [12], diabetes by
65% [13] and some cancers by 40% [14] and reduces all-
cause mortality by 33% and cardiovascular mortality by
35% [15]. Accordingly, supporting people to be more
physically active can improve both patient’s health and
decrease the economic burden these diseases place on
the NHS. To date, no interventions aimed to increase
physical activity following joint replacement surgery
have been robustly tested. To address this, the PEP-
TALK trial was undertaken.
Methods
Trial design
The trial is an open, phase III, pragmatic, parallel, two-
arm, two-way superiority randomised controlled trial
(RCT) on individuals investigating the effectiveness of
usual care plus a group exercise and behaviour-change
intervention versus usual care alone to increase physical
activity following primary THR or TKR. Neither partici-
pants nor physiotherapists can be blinded to the treat-
ment allocation. Primary comparison is assessed at 12
months post-randomisation with data being collected at
baseline (pre-operatively), 6 months and 12months
post-randomisation.
Participants will be screened for inclusion in the trial
pre-operatively, consented pre-operatively and eligibility
confirmed post-operatively. They will then be rando-
mised prior to hospital discharge and notified of their
group allocation to facilitate the organisation of their re-
habilitation. Initially, participants were randomised to
the two groups 1:1 using minimisation by trial centre,
type of joint replacement (THR or TKR), and Charlson
co-morbidity index (1–3 or ≥4). The minimisation algo-
rithm will have a probabilistic element of 0.8 included to
ensure unpredictability of treatment assignment.
After 75 randomisations, the random allocation ratio
was changed to 2:1 (Experimental Intervention: Usual
Care). This change was made to ensure more partici-
pants were randomised to the experimental intervention
group. The intervention is group-based and is designed
to have three or more participants per group session.
Based on evidence from early recruiting sites, there was
difficulty to consistently fill sessions under a 1:1 alloca-
tion ratio. Therefore this change was deemed important
to facilitate larger groups. This change was implemented
by the Trial Management Group and approved by the
Data Safety Monitoring Committee, Sponsor and Re-
search Ethics Committee.
Those randomised to usual care (the comparator) will
receive six, 30-min group-based exercise sessions. Those
randomised to the experimental intervention will receive
six group-based behaviour change intervention sessions
(30-min duration) immediately followed by the control
intervention of 30 min of group-based exercise and three
follow-up telephone calls up to 6 weeks after completing
the group sessions. Both group’s physiotherapy will
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commence within the initial four weeks post-
randomisation and continue weekly for 6 weeks. Further
details of the trial design and procedures, including full
eligibility criteria and trial interventions are found in the
PEP-TALK trial protocol [16].
Outcomes
Primary outcome
The primary outcome measure is the UCLA Activity
Score 12 months post-randomisation. The UCLA Scale
is a reliable and valid self-reported tool to assess physical
activity [17, 18] that assesses global activity levels with a
grading system of 1 to 10 where 1 equates to “wholly in-
active, dependant on others and cannot leave residence”
and 10 refers to “regularly participates in impact sports”.
Secondary outcomes
The secondary outcome measures, self-reported with
partial answers being coded as missing and collected at
baseline (except complications), 6 and 12months post-
randomisation unless otherwise stated, are as follows:
 Functional outcome: Lower Extremity Functional
Scale (LEFS) [19]. A questionnaire containing 20
questions scored using a scale 0-80 with a higher
score representing a higher functional level.
 Disease specific function: Oxford Hip Score/Oxford
Knee Score (OHS/OKS) [20, 21]. A 12-item disease-
specific questionnaire, scores range from 0 to 48
where 48 indicates high joint function. Murray et al.
[22] recommends to impute the mean value repre-
senting all other items to fill in two or fewer missing
items.
 Perceived level of pain: Numerical Rating Scale
(NRS) for Pain. An 11-point scale where participants
mark their perceived pain between 0 representing
‘no pain’ to 10 representing the ‘worst possible pain’.
 Self-efficacy: Generalized Self-Efficacy Scale (GSES)
[23]. A 10-item scale with scores ranging from 10 to
40, higher scores representing a high level of self-
efficacy.
 Fear avoidance: Tampa Scale for Kinesiophobia [24].
A 17-item self-completed questionnaire with scores
from 17 to 68 where the higher scores indicate an
increasing degree of kinesiophobia.
 Psychological distress: Hospital Anxiety and
Depression Scale (HADS) [25]. This scale consists of
14 items divided into two 7-item subscales: Anxiety
and Depression. The total score is out of 42 (21 per
subscale), higher scores indicate greater levels of
anxiety/depression or global psychological distress.
 Health-related quality of life: Euroqol EQ-5D-5L
[26]. A patient-reported health-related quality of life
questionnaire consisting of two parts. First, five
domains related to daily activities with a 5-level an-
swer possibility are measured [26, 27], which will be
converted into multi-attribute utility scores using
established algorithm [28]. To calculate EQ-5D-5L
Index scores the Crosswalk Index Value Calculator
will be used to map the 5L descriptive system data
onto the 3L dataset using the mapping function de-
veloped by van Hout et al. [27] as, at the time of
writing this statistical analysis plan, there is still de-
bate about the appropriate value set for the 5L. Sec-
ondly, the Euroqol VAS (EQ-VAS) is a 0 to 100
visual analogue score from the worse (0) to best
health imaginable (100). Any participant who dies
will have their EQ-5D-5L Index imputed as a score
of zero for all time points after death, their EQ-VAS
scores will be missing data for those time points.
 Complications and adverse events will be collected
throughout the trial.
Sample size
Two hundred fifty participants (125 per arm) are re-
quired to detect a standardised effect size of 0.4 with
80% power and 5% (2-sided) significance, allowing for
20% loss to follow-up. These calculations are based on
the primary outcome at 12 months post-randomisation,
assuming a baseline standard deviation of 2.5 [17] and a
between-group difference of one. Our target standar-
dised effect size is derived from the UCLA Activity
Score’s minimal clinically important difference of 0.92
[17]. The sample size was increased to 260 to account
for the change in allocation ratio, maintaining the same
power and type I error rate.
Effect of COVID-19 pandemic
The COVID-19 pandemic impacted on the conduct of
the PEP-TALK trial. All elective surgeries, including
THRs and TKRs, were cancelled as part of the UK na-
tional lockdown (23rd March 2020) and group-based
physiotherapy classes within the hospital outpatient set-
ting (a mechanism the trial relies on for both treatment
groups) was stopped indefinitely.
A direct consequence of the cancellation of THRs and
TKRs was that the trial was no longer able to randomise
eligible and consented participants and was forced to
close recruitment prematurely (230 final randomisations
of the minimum sample size of 260).
As the trial had been open to recruitment for less than
12months by March 2020, none of the randomised par-
ticipants reached the full 12-month follow-up without
being affected by the COVID-19 lockdown. This is par-
ticularly noteworthy in this instance as participants are
likely to be in a demographic more medically vulnerable
to the pandemic and all outcomes are assessed through
Patient Reported Outcome Measures (PROMs). It is
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hypothesised the lockdown will be a confounder whilst
assessing these outcomes, particularly those pertaining
to more psychological aspects (e.g. the GSES) which may
have been impacted by COVID-19 social measures on
behaviour. However, as the trial is randomised, this ef-
fect should be the same across both treatment groups
and therefore should not affect the overall treatment ef-
fect estimate.
An indirect consequence of the pandemic on the trial
is that it is possible, in a ‘post-COVID-19 world’, that
what is considered “usual care” will be different to how
that was perceived at the time of the trial’s conception
(2016–2017). This has a potential effect on the generalis-
ability of the results. The trial is pragmatic by nature
and every effort has been made to follow-up participants
to ascertain what intervention they actually received.
Through reporting this information, it is hoped this trial
will give a non-conclusive indication of what usual care
was during this change in practice as a result of the
COVID-19 pandemic and the effectiveness of it.
Due to the effects of the pandemic, analysis and data
exploration unforeseen when writing the protocol have
been included in this analysis plan. These additions,
found in the relevant section of this paper, will assess
the effect of the pandemic on the trial and provide in-
sights on future physiotherapy service configuration.
Note: The terms ‘COVID-19 status’ and ‘pre-COVID-
19/COVID-19’ groups used within this paper refer to
the definitions outlined in the ‘Definition of analysis
populations’ section. This does not refer to participants
who tested positive for COVID-19; testing information
has not been collected as part of this trial.
Statistical analysis
General analysis principles
There is one planned final analysis, which will occur 12
months after the final participant’s randomisation, allow-
ing for an appropriate time for the data to be collected,
cleaned and prepared for final analysis. There is no mul-
tiple testing as only a single primary outcome is consid-
ered. Significance levels used will be 0.05 and 95%
confidence intervals will be reported. Any analyses not
pre-specified will be exploratory in nature and a signifi-
cance level of 0.01 will be used to declare statistical sig-
nificance and 99% confidence intervals will be presented.
No formal interim analysis or predefined early stopping
rules are planned for this trial.
Definition of analysis populations
 Intention-to-treat: inclusion of all available
randomised participants who will be analysed in the
groups to which they were randomly allocated
irrespective of non-compliance. If a participant has
observed data on any of the follow-up time points,
they will be included in the analysis.
 Per protocol: eligible participants who received the
treatment they were randomised to with data on the
primary outcome at 12 months. Participants who
had major protocol violations/deviation (e.g. not
have received the treatment they were allocated to)
will be excluded from this population.
 Strict compliers: participants who fall under the
Strict Compliance definition outlined in the
‘Compliance’ section.
 Compliers: participants who fall under the
Compliance definition outlined in the ‘Compliance’
section.
 Attenders: participants who fall under the
Attendance definition outlined in the ‘Compliance’
section.
 Pre-COVID-19: participants who completed their
intervention before national UK lockdown (23rd
March 2020) and had no disruption to their planned
treatment.
 COVID-19: participants who did not receive any
intervention before 23rd March 2020 or had their
intervention delivery disrupted by the UK lockdown.
Descriptive analysis
The flow of participants through each stage of the trial,
including the number of individuals screened, eligible,
randomised to each group, receiving allocated treatment,
and included in the primary analysis will be summarised
using a CONSORT flow chart (Fig. 1). Reasons for ineli-
gibility, loss to follow-up and exclusion from the primary
analysis will be summarised. Participant follow-up data
will be presented by randomised group as well as
COVID-19 status (pre-COVID-19/COVID-19 as in the
‘Definition of analysis populations’ section).
Baseline characteristics will be reported by the treat-
ment group, including the minimisation factors and im-
portant prognostic, demographic and clinical covariates.
Numbers (with percentages) for binary and categorical
variables and means (and standard deviations), or me-
dians (with lower and upper quartiles) for continuous
variables will be presented, there will be no tests of stat-
istical significance nor confidence intervals for differ-
ences between randomised groups on any baseline
variable. Baseline characteristics will also be reported by
COVID-19 status in order to explore the difference in
demographics between these groups.
It is likely that some data may not be available due to
voluntary withdrawal of participants, lack of completion
of individual data items or general loss to follow-up. The
number (with percentage) of withdrawals from the trial
and the numbers lost to follow-up for the primary out-
come together with the associated reasons (where
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Fig. 1 CONSORT diagram
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possible) will be reported by the treatment group. Any
deaths (and their causes) will be reported separately.
Compliance
Deviations from intended treatment (non-adherence to
the protocol) will be summarised for the randomised
groups; these will include non-compliance and with-
drawal of consent. Details of compliance and what inter-
vention was actually received will be reported by the
treatment group and also separately by COVID-19 sta-
tus. Three levels of compliance: Strict Compliance,
Compliance and Attendance have been defined as
follows:
1. Strict Compliance (as defined in the original
Protocol [16]):
Usual Care group:
 Attends at least four out of six physiotherapy
sessions
Experimental Intervention group:
 Attends at least four out of six group intervention
sessions with a minimum of three participants per
session
 Receives two out of three follow-up telephone calls
2. Compliance:
Usual Care group:
 Attends at least four out of six physiotherapy
sessions
Experimental Intervention group:
 Attends at least four out of six group intervention




 Attends at least one out of six physiotherapy
sessions
Experimental Intervention group:
 Attends at least four out of six group intervention
sessions.
Other indicators of compliance to the rehabilitation
exercises (i.e. data collected from Exercise Diaries) may
be summarised by treatment group in tabular or graph-
ical form. The effect of changing the randomisation ratio
from 1:1 to 2:1 after 75 randomisations on levels of com-
pliance will also be explored.
Analysis of the primary outcome
The primary outcome measure, the role of usual care
versus usual care plus the experimental intervention
upon the UCLA Activity Score at 12 months post-
randomisation, will be modelled using a mixed effects
model. This model will account for person within centre
random effects, and Charlson Comorbidity Index score
and baseline UCLA Activity Score (as continuous out-
comes), type of operation the patient is undergoing
(THR or TKR), time (6 or 12 months) and treatment as
fixed effects. Treatment by time point interactions will
also be included in the model to allow time-specific
treatment effects to be calculated. This model uses all
available data at each time point. Comparison will be
performed on an intention-to-treat basis and results pre-
sented as comparative summary statistics (i.e. difference
in means) with 95% confidence intervals.
The appropriateness of the assumption of approximate
normality of the residuals of this model will be assessed
graphically. If the residuals are not normally distributed,
the outcome data will be log-transformed to gain nor-
mality and geometric means with 95% confidence inter-
vals will be reported. If data is not normally distributed
after log-transformation, the non-parametric Mann-
Whitney test will be used with no adjustment for base-
line or stratification factors, and the difference in me-
dians with 95% confidence intervals will be reported.
Supporting analyses of the primary analysis
An area under the curve (AUC) analysis will be per-
formed for the UCLA Activity Score. Estimates will
come from the same mixed model used in the analysis
of the primary outcome except including baseline UCLA
Activity Score in the ‘time’ fixed effect allowing time
point-specific treatment effects to be calculated for base-
line, six months and 12 months. These estimates will be
used to calculate the AUC. Using the estimates from the
mixed-effects model rather than raw, unadjusted esti-
mates results in less bias estimates of the AUC when
missing data are present [29].
Complier average causal effect (CACE) analyses will be
performed to find estimates for the causal effect of actu-
ally receiving the treatment and the overall treatment ef-
fect (including non-compliers) through intention to treat
analysis. The definitions of Strict Compliance, Compli-
ance and Attendance will be used to perform three
CACE analyses.
A supporting analysis of the primary outcome will use
a three-level model with participants within
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predominant treating physiotherapist within the centre
to examine the potential physiotherapist (random) ef-
fects. This model will formally incorporate terms that
allow for possible heterogeneity in responses for partici-
pants due to the recruiting centre and the physiotherap-
ist. The model will include the same fixed effects used in
the primary analysis model as well as treatment by time
point interactions.
An additional supporting analysis of the primary out-
come using a reduced version of the primary analysis
model, only using a person as a random effect, will be
performed. This model is pertinent as Usual Care should
be homogenous across the recruiting centres in a prag-
matic trial so using a simpler model may yield a better-
fit model. Model fit compared to the primary analysis
model will be assessed using information criteria.
Analysis of the secondary outcomes
The continuous secondary outcomes, to compare func-
tional outcomes, disease-specific function, perceived
level of pain, self-efficacy, fear avoidance, psychological
distress and health-related quality of life between groups,
are assessed through the corresponding PROMs mea-
sured at baseline, 6 months and 12months post ran-
domisation. Mixed effects models, as used in the
primary analysis, will be used to assess these outcomes.
These models will account for person within centre ran-
dom effects, and Charlson Comorbidity Index score and
the relevant baseline PROM score (as continuous out-
comes), operation type, time (6 or 12 months) and treat-
ment as fixed effects. Treatment by time point
interactions will also be included in the model to allow
time-specific treatment effects to be calculated.
There is expected to be a low number of complica-
tions/serious adverse events (SAEs) in this trial. Any ad-
verse events (AEs) occurring whilst a participant is
continuing in the study, until completion of the final
study visit will be recorded. All AEs will be reported and
tabulated by grade and treatment group—similar report-
ing will be done with SAEs. The number of SAEs and
the number of participants reporting one or more SAEs
will be reported by the treatment group. If there is a
large enough number of events for a comparison to be
appropriate, then the complications in each group will
be pooled and the ‘Total Complications’ analysed by cal-
culating the odds ratio and 95% confidence interval
using logistic regression adjusting for minimisation fac-
tors (recruiting centre, Charlson Comorbidity Index (as
a continuous value) and type of operation) and
treatment.
Sensitivity analyses
Sensitivity analysis will assess the internal validity of the
trial results by performing a per-protocol analysis on all
participants who fall under the per-protocol definition as
per the ‘Definition of analysis populations’ section.
Missing data Missing data analysis will be performed
on the primary outcome only. The primary analysis
multi-level model using repeated measures is relatively
robust to missing data under the missing at random
(MAR) assumption [30].
Analysis will be performed on an intention-to-treat
basis. The number and percentage of participants in the
missing category will be presented, as well as reasons for
missingness if known. Missing data will be reported and
summarised by the treatment group. The distribution of
missing data will be explored to assess the assumption
of data being missing at random under which the princi-
pal analyses will be conducted. Varying scores of the
UCLA Activity Score (e.g. 30th, 40th, 50th, 60th, 70th
quantiles) will be imputed where data is missing and
these ‘complete’ datasets will be reanalysed, using the
same model used in the primary analysis and the results
presented in graphical form. This analysis will be under-
taken if there is more than 5% missing data for the pri-
mary outcome at 12 months.
If there is evidence that there is a departure from the
MAR assumption, a search for factors not included in
the primary analysis model that explains missingness will
be performed and if variables are found, multiple-
imputation using chained equations [31] will be utilised,
using the primary analysis model but including these
variables to assess the sensitivity of the findings to miss-
ing data. If no variables are identified, multiple-
imputation will not be performed.
Pre-specified subgroup analysis
All subgroup analyses will be on the primary outcome
only. Subgroup analyses of the two clinical stratifying
variables (type of operation and (THR or TKR), Charl-
son Comorbidity Index Score (1–3 or ≥ 4)) are planned.
A subgroup analysis of COVID-19 status will also be
performed. These will use an extended primary analysis
model including an interaction term between treatment
and each stratifying variable/COVID-19 status to define
the subgroups. Subgroup analyses will be labelled as ex-
ploratory, and results will be interpreted with due cau-
tion, in line with recommendations for subgroup
analysis made elsewhere [32]. The results will be pre-
sented in a forest plot.
Additional analysis
A mediation analysis will be carried out. A priori medi-
ation analysis mediators will include self-efficacy, fear
avoidance, pain and psychological distress to compare
the mediation pathways presented in the BeST interven-
tion [33] to the PEP-TALK intervention.
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An additional analysis will be performed to assess the
effect of COVID-19 on the activity at 12 months post-
randomisation. The model used for the primary analysis
will be extended to include COVID-19 status (as a fixed
effect) and a COVID-19 status by time point interaction.
The adjusted mean difference of COVID-19 status will
be reported with supporting 95% confidence intervals. It
should be noted that formally investigating COVID-19
status’ effect on activity is outside the scope of the ori-
ginal trial design so results from this analysis are
hypothesis-generating and exploratory.
Descriptive statistics on secondary outcomes of GSES,
the Tampa Scale for Kinesiophobia, HADS, EQ-5D-5L
Index, EQ-VAS and NRS for pain may be produced to
further assess the impact of COVID-19. No formal ana-
lysis to examine the relationship between COVID-19
status and secondary outcomes will be performed.
Statistical packages
All analysis will be carried out using STATA [34] or R
[35] statistical software. The package and version num-
ber used for analysis will be recorded and reported.
Discussion
This paper provides details of the planned statistical ana-
lyses for the PEP-TALK trial to reduce the risks of
reporting bias [36] and includes pre-specified analyses
planned to explore the effect of COVID-19. Any changes
or deviations from the analysis outlined in this paper will
be described and justified fully in the final report.
Trial status
The first participant was randomised into the study on
the 12th of April 2019, final randomisation occurred on
the 27th of March 2020. Randomisations were stopped
due to COVID-19, 44 potential participants had con-
sented and were awaiting surgery prior to randomisation
when the trial closed. In total 230 participants, from
eight participating centres, were randomised. Follow-up
is currently ongoing and is expected to finish in April/
May 2021 with the final data lock occurring in Summer
2021. All analyses being conducted thereafter.
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